Modeling the efficacy of a novel antidepressant zuranolone for major depressive disorder.

This research aimed to quantify the treatment potential of zuranolone-a novel positive allosteric GABAA receptor modulator-in adults with major depressive disorder (MDD). Publicly available databases were systematically searched to identify randomized, placebo-controlled trials. We used changes in rating scale scores from baseline to perform a model-based meta-analysis, characterizing the progression of drug efficacy and placebo response over time and comparing zuranolone's efficacy and safety profiles with those of established antidepressants (escitalopram and amitriptyline). Pharmacokinetic modeling and meta-analysis frameworks were applied to assess efficacy and placebo response characteristics. A total of 37 trials (N = 8735 individuals) were incorporated in the final analysis. Zuranolone exhibited a rapid onset of action (k = 0.75 day-1), 10-fold and 27.8-fold faster than amitriptyline (k = 0.075 day-1) and escitalopram (k = 0.027 day-1), respectively. Amitriptyline exhibited the highest pure efficacy, continuously increasing over time. The 95 % confidence intervals (CIs) of zuranolone and escitalopram overlapped, suggesting similar efficacy. Zuranolone achieved significant symptom improvement within two weeks of treatment (-6.64 %, 95 % CI: -9.77 % to -3.39 %) and sustained efficacy through four weeks post-treatment. The dropout rate was lower with zuranolone (2.4 %, 95 % CI: 1.5 to 3.3 %) than with escitalopram (4.5 %, 95 % CI: 3.0 to 5.9 %). Primary adverse events related to zuranolone included somnolence, headache, dizziness, and sedation, with no severe safety signals observed. Zuranolone demonstrates a safety profile comparable to escitalopram as well as rapid-onset antidepressant action, sustained clinical efficacy, and favorable tolerability, highlighting its potential as a promising therapeutic option for MDD.